BNP Paribas Financial Markets
SYRE icon

BNP Paribas Financial Markets’s Spyre Therapeutics SYRE Stock Holding History

BNP Paribas Financial Markets’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1M Buy
259,923
+241,293
+1,295% +$17.6M 0.01% 1173
2026
Q1 		$940K Buy
18,630
+6,786
+57% +$256K ﹤0.01% 3174
2025
Q4 		$388K Sell
11,844
-304,065
-96% -$7.95M ﹤0.01% 3708
2025
Q3 		$5.29M Buy
315,909
+92,589
+41% +$1.51M ﹤0.01% 1935
2025
Q2 		$3.34M Buy
223,320
+167,487
+300% +$2.48M ﹤0.01% 2132
2025
Q1 		$901K Buy
55,833
+37,049
+197% +$771K ﹤0.01% 2862
2024
Q4 		$437K Buy
+18,784
New +$551K ﹤0.01% 3380
2023
Q3 		– Hold
0
– – – 4036
2023
Q2 		– Sell
-16
Closed -$76 – 4018
2023
Q1 		$115 Sell
16
-103
-87% -$1.13K ﹤0.01% 3774
2022
Q4 		$1.33K Buy
119
+56
+89% +$1.01K ﹤0.01% 3773
2022
Q3 		$828 Sell
63
-148
-70% -$1.83K ﹤0.01% 4454
2022
Q2 		$2.66K Buy
211
+68
+48% +$2.38K ﹤0.01% 3857
2022
Q1 		$8.23K Sell
143
-303
-68% -$25.4K ﹤0.01% 3827
2021
Q4 		$53K Buy
446
+16
+4% +$2.52K ﹤0.01% 3728
2021
Q3 		$85.5K Buy
430
+242
+129% +$42.3K ﹤0.01% 3332
2021
Q2 		$32.7K Sell
188
-90
-32% -$16.4K ﹤0.01% 3404
2021
Q1 		$55.1K Sell
278
-74
-21% -$14.2K ﹤0.01% 3587
2020
Q4 		$69.3K Sell
352
-46
-12% -$9.53K ﹤0.01% 3403
2020
Q3 		$70.5K Buy
398
+321
+417% +$59.4K ﹤0.01% 3299
2020
Q2 		$17.9K Sell
77
-246
-76% -$46.9K ﹤0.01% 3445
2020
Q1 		$37.6K Buy
323
+194
+150% +$33K ﹤0.01% 3683
2019
Q4 		$24.6K Sell
129
-9
-7% -$1.77K ﹤0.01% 3940
2019
Q3 		$26.6K Buy
138
+51
+59% +$9.93K ﹤0.01% 3822
2019
Q2 		$14.9K Sell
87
-74
-46% -$12.8K ﹤0.01% 3999
2019
Q1 		$32.5K Buy
+161
New +$33.6K ﹤0.01% 3741
2018
Q4 		– Sell
-21
Closed -$5.1K – 4415
2018
Q3 		$5.1K Hold
21
– – ﹤0.01% 4052
2018
Q2 		$5.64K Buy
+21
New +$5.17K ﹤0.01% 4046

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BNP Paribas Financial Markets's SYRE Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Spyre Therapeutics (SYRE) stake by 1,295% in Q2 2026, buying an estimated $17.6M and bringing the position to 259,923 shares worth $23.1M. The position accounts for 0.01% of the portfolio, ranked #1173.

BNP Paribas Financial Markets first reported a position in SYRE in Q2 2018 and has held it in 26 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • BNP Paribas Financial Markets held 259,923 shares of Spyre Therapeutics worth $23.1M as of Q2 2026.
  • BNP Paribas Financial Markets bought 241,293 Spyre Therapeutics shares in Q2 2026, an estimated $17.6M.
  • Spyre Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1173 holding.
  • BNP Paribas Financial Markets first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 26 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.